Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Date:4/23/2008

tion, MT110 may be suited to treat established tumors as well as disseminated cancer cells, which frequently give rise to metastases."

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting EpCAM (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with lung and gastrointestinal cancers. Two additional BiTE antibodies, targeting CD33 and MCSP, are in preclinical development.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and auto
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 Z-Medica, a ... it has launched the first-ever line of products designed ... The line includes QuikClot ® EMS 4x4 Dressing, ... ® EMS Rolled Gauze™, all custom-designed to help ... they can be transported to a hospital or trauma ...
(Date:5/22/2013)... 22, 2013  MGT Capital Investments, Inc. (NYSE MKT: ... the Second Annual Marcum LLP MicroCap Conference on Thursday, ... at the Grand Hyatt Hotel.  ... will update investors and answer questions. (Logo: ... is scheduled to begin at 9:30 a.m. EDT.  MGT,s ...
(Date:5/22/2013)... , May 22, 2013 Hemoglobin A1C ... patients with Type 2 diabetes, while modest improvements ... health outcomes and can lead to substantial healthcare ... the International Society for Pharmacoeconomics and Outcomes Research ... two studies, sponsored by Valeritas, makers of the ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... 21, 2011  BARRX Medical Inc., a leader in developing ... to remove precancerous tissue from the gastrointestinal tract, announces ... be acquired by Covidien.  Covidien is a leading global ... advanced energy-based devices.  Covidien will acquire ...
... NORRITON, Pa., Nov. 21, 2011 Tengion, Inc. (NASDAQ: ... today announced that Brian Davis, Vice President Finance and ... upcoming Piper Jaffray 23rd Annual Health Care Conference on ... A live audio webcast of the presentation ...
Cached Medicine Technology:BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
(Date:5/22/2013)... 22, 2013 Today, Zane Benefits, Inc. ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... Benefits’ website, beginning in 2014 as part of the ... and small businesses will become available through new state ...
(Date:5/22/2013)... Hopkins researchers report that hospitals may be reaping ... complicated by preventable bloodstream infections contracted in their ... study, reported online in the American Journal ... an ICU patient who develops an avoidable central ... more to care for than a similar infection-free ...
(Date:5/22/2013)... 22, 2013 Registered Dietitian and Founder of ... on Tatalou.com sharing a recipe for making energy bars at ... Energy Bars ,” takes a recipe modified from one ... , “Every day it gets more and more difficult to ... Chevreau. “The size of the nutrition label continues to grow ...
(Date:5/22/2013)... Unknown to the citizens of Wichita, Kansas a tornado was ... it struck, the city’s warning siren started blaring and informed ... to reach safety and prevented any deaths or injuries. ... product that will increase safety in the workplace if a ... System provides employees with the same type of warning ...
(Date:5/22/2013)... (HealthDay News) -- People with heart failure are more ... gland that is even mildly underactive, according to a ... researchers found an increased risk of death linked to ... "This study is the first to show that African-Americans ... than patients of other racial and ethnic groups," Dr. ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2Health News:Underactive Thyroid and Heart Failure a Bad Combination: Study 2
... BOARD,S INTERESTS ARE NOT ALIGNED WITH STOCKHOLDERSADVOCAT BOARD NEEDS ... Calif., May 19 Bristol Investment Fund, Ltd. ("Bristol") ... the stockholders of Advocat, Inc. (the "Company") (Nasdaq: ... highly qualified and independent director nominees, Paul Kessler and ...
... microsite (www.meettheburns.com) targets first time athlete,s foot sufferers ... Schering-Plough Corporation (NYSE: SGP ... an antifungal spray for the treatment of athlete,s ... liquid spray and deodorant powder spray.(Photo: ...
... Sustainable Healthcare CHICAGO, May 19 Practice ... to environmentally responsible healthcare, has announced its ... competitive awards are given to institutions within ... reduce the facility,s environmental footprint.Fletcher Allen Health ...
... differ across continents, posing challenges to drug launches. ... regulatory environment of the European Union (EU) and ... less price controlled markets witness quicker launches, while ... industry, along with regulatory agencies, has been working ...
... 2009 The International Diabetes Federation (IDF), International ... (WHF) today issued a joint statement that calls ... epidemic of non-communicable diseases (NCDs), responsible for 35 ... substantial increase in funding for NCDs and greater ...
... in the Los Angeles , California area will be ... describe a revolutionary laser liposuction procedure. Dr. ... Center is one of the first surgeons on ... laser liposuction technique -- that not only melts fat, ...
Cached Medicine News:Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 2Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 3Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 4Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 5Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 6Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 7Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 8Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 9Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 3Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 4Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 5Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 6Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 7Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 8Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 3Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 4Health News:Leading NGOs call for international action to combat epidemic of noncommunicable diseases 2Health News:Leading NGOs call for international action to combat epidemic of noncommunicable diseases 3Health News:Leading NGOs call for international action to combat epidemic of noncommunicable diseases 4Health News:Los Angeles Cosmetic Plastic Surgeon Dr. Christine Petti and Smartlipo Featured on Upcoming Episode of The Doctors 2Health News:Los Angeles Cosmetic Plastic Surgeon Dr. Christine Petti and Smartlipo Featured on Upcoming Episode of The Doctors 3Health News:Los Angeles Cosmetic Plastic Surgeon Dr. Christine Petti and Smartlipo Featured on Upcoming Episode of The Doctors 4
The Diamedix immunosimplicity® Is- Rheumatoid Factor Test Kit is an EIA procedure intended for the quantitation of IgM antibodies to IgG antigen. The results are reported in IU/mL, traceable to t...
... The SYNCHRON CX4 Delta Specialty / ... access analyzer that can consolidate Drugs ... testing, such as thyroid, HbA1c and ... CX4 Delta offers a level of ...
Inquire...
... Analyzer is a high precision optical system ... of the anterior eye segment, based on ... a Placido Disk. , GALILEI combines the ... high accuracy curvature data, while Scheimpflug imaging ...
Medicine Products: